Viscosupplementation Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

Viscosupplementation Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

Global Viscosupplementation market size is projected to reach US$ 7.81 Billion by 2030, as per Renub Research. Hyaluronic acid (HA) injections are typically used for treating localized osteoarthritis (OA) due to their easy application and tolerability. Many HA derivatives are available, with various properties and ranges of proof. Viscosupplementation is moderately but appreciably effective in reducing pain and improving feature in comparison to a placebo. It has a high rate of positive responses while used to treat knee osteoarthritis. It can help lessen the need for opioid analgesics and NSAIDs, ensuing in an improved risk/gain ratio, and might additionally put off the need for joint replacement.

The prevalence of age-related illnesses is increasing with the arena's growing older populace, with osteoarthritis being the maximum commonplace joint disorder. Osteoarthritis is related to excessive scientific and social changes. Viscosupplementation, which involves injecting hyaluronic acid derivatives into the joint, is becoming a more famous remedy method. The materials applied in this procedure are high molecular-weight polysaccharides. These distribute weight, lubricate the joint and exhibit anti-inflammatoryproperties. Additionally, those drugs exert physical-chemical outcomes on various joint characteristics. The importance of those results is contingent upon the molecular weight and attention of the drug, alongside the presence of any cross-links within the drug.

Viscosupplementation Market is expected to grow at a compound annual growth rate (CAGR) of 8.97% from 2024 to 2030

Viscosupplementation, an outpatient procedure, effectively alleviates pain and enhances joint function in osteoarthritis patients. It contributes to the augmentation of joint cartilage in terms of quality and quantity. With a commendable safety record and cost-effectiveness, this procedure is often recommended post-arthroscopy. Knee and hip osteoarthritis prevalence is rising among older people due to age-related factors impacting cartilage strength and flexibility. The aging population, expected to double to 1.5 billion by 2050, is a global trend reported by the United Nations. By 2043, seniors constituted about 25% of Canada's total population, as per government statistics.

The viscosupplementation market is expanding, propelled by the widespread adoption of key strategies like collaboration, acquisition, agreements, and company partnerships. A primary growth driver is the increasing prevalence of osteoporosis and osteoarthritis (OA). This has led to heightened adoption of viscosupplementation in the healthcare sector for managing joint pain—an appealing, minimally invasive alternative to corticosteroids. The market benefits significantly from this shift. Moreover, consumer awareness of the advantages of non-surgical treatments, including cost-effectiveness, absence of hospitalization, minimal complications, and improved clinical outcomes, amplifies this trend, further fueling the market's growth.

Favorable government policies and substantial investments by pharmaceutical companies in novel drugs and alternative administration routes propel growth in the healthcare industry. This expansion is bolstered by the emergence of ambulatory surgical centers (ACS), addressing surgical and non-surgical issues in joints, ligaments, muscles, spine, and nerves. The market receives an additional boost from introducing open-label single-injections with hyaluronic acid, actively driving industry growth.

The viscosupplementation market is experiencing positive impacts from factors like favorable health insurance reimbursement policies, a growing population with chronic disabilities, and an increasing geriatric demographic susceptible to chronic ailments. Collaborations, partnerships, and continuous research and development (R&D) activities in the medical sciences further contribute to this growth. In 2023, the viscosupplementation market reached a valuation of US$ 4.28 Billion.

Segment of single-injection viscosupplementation is anticipated to experience growth in the future

The Viscosupplementation market is segmented by Product into Single Injection, Three Injection, and Five Injection. The single-injection viscosupplementation segment is poised for substantial growth in the coming years. This anticipated expansion is attributed to several factors:

1. The single-injection approach provides enhanced convenience for both physicians and patients.
2. There is a rising demand for outpatient surgeries, particularly those emphasizing same-day surgical care, encompassing preventive and diagnostic procedures.
3. Companies are intensifying their efforts to develop single-injection treatments for osteoarthritis, resulting in increased product launches.

The growing focus on offering efficient solutions for osteoarthritis patients aligns with the overall strategy of developing single-injection products, contributing to the anticipated growth of the viscosupplementation market throughout the forecast period.

Knee osteoarthritis emerged as the dominant force in the viscosupplementation market

By application, the Viscosupplementation market is divided into Knee, Hip, Hand/Wrist, Ankle/Foot, and Others. The knee osteoarthritis segment has asserted its dominance in the viscosupplementation market, primarily fueled by the escalating prevalence of knee osteoarthritis and the increasing geriatric population, which is more prone to this condition. The aging demographic is particularly susceptible to knee osteoarthritis due to the aging process, leading to a reduction in the water content of cartilage. This diminishes its capacity to absorb shock and provide cushioning, making older people more susceptible to knee-related ailments. The significant prevalence of knee osteoarthritis and its correlation with age underscore the prominence of this segment within the viscosupplementation market.

Orthopedic clinics/Ambulatory Surgical Centers market is rising year on year

By End User, the Viscosupplementation market is classified into Hospitals and orthopedic clinics/Ambulatory Surgical Centers. The orthopedic clinics and ambulatory surgical centers market is witnessing consistent annual growth. This trend indicates the increasing demand for specialized orthopedic services and the adoption of outpatient surgical procedures. Patients increasingly prefer these facilities for convenience, efficient services, and reduced hospitalization time. Additionally, advancements in medical technology and the emphasis on providing comprehensive orthopedic care contribute to the sustained expansion of this market. As healthcare continues to evolve towards more patient-centric models, the growth of orthopedic clinics and ambulatory surgical centers reflects the changing landscape of orthopedic healthcare services.

China will be the second-largest contributor to the market

By Countries, Viscosupplementation market is split into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand), South America (Brazil, Mexico, Argentina), Middle East & Africa (South Africa, Saudi Arabia, UAE). The expansion of the viscosupplementation market in China is influenced by diverse factors such as population demographics, disease incidence, prevalence, macroeconomic conditions, and geopolitical considerations. Market fluctuations may arise from unexpected shifts in these elements and alterations in clinical practices that result in modifications to patient diagnosis or treatment approaches, reflecting a broader effort to enhance overall medical practices.

The U.S. viscosupplementation market is growing due to a rising osteoarthritis population seeking non-surgical solutions. As per the CDC, about 34.5 million Americans contend with osteoarthritis annually, marked by reduced hyaluronic acid leading to pain and stiffness. Increased interest in non-surgical options, driven by concerns over surgery and treatment costs, contributes to market growth. Ongoing advancements in hyaluronic acid therapies, tailored by key players for swift knee pain relief, further propel the market. Researchers are also exploring diverse strategies to impede the progression of knee pain disorders amidst this growth trend.

Key Player

Anika Therapeutics Inc., Zimmer Biomet, Smith & Nephew PLC, F.Hoffmann-La Roche Ltd, Sanofi, Chugai Pharmaceutical Co., Lifecore Biomedical, and LG Life Sciences Ltd are the leading companies in the Viscosupplementation market.

Renub Research latest report “Global Viscosupplementation Market Forecast by Product (Single Injection Viscosupplementation, Three Injections Viscosupplementation and Five Injections Viscosupplementation), By Application (Knee, Hip, Hand/Wrist, Ankle/Foot, and Others), by End User (Hospitals, Orthopedic Clinics/Ambulatory Surgical Centres), By Region (North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand), South America (Brazil, Mexico, Argentina), Middle East & Africa (South Africa, Saudi Arabia, UAE)), Key Players Analysis (Anika Therapeutics Inc, Zimmer Biomet, Smith & Nephew PLC, F.Hoffmann-La Roche Ltd, Sanofi, Chugai Pharmaceutical Co, Lifecore Biomedical and LG Life Sciences Ltd)” provides a detailed analysis of Global Viscosupplementation Industry.

Product – Market have been covered from 3 viewpoints

1. Single Injection Viscosupplementation
2. Three Injections Viscosupplementation
3. Five Injections Viscosupplementation

Application – Market have been covered from 5 viewpoints

1. Knee
2. Hip
3. Hand/Wrist
4. Ankle/Foot
5. Others

End User – Market have been covered from 2 viewpoints

1. Hospitals
2. Orthopedic clinics/Ambulatory Surgical Centers

Region – Market have been covered from 25 Countries viewpoints

1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa

Company Analysis

• Overview
• Recent Development
• Revenue

Companies Covered

1. Anika Therapeutics Inc
2. Zimmer Biomet
3. Smith & Nephew PLC
4. F.Hoffmann-La Roche Ltd
5. Sanofi
6. Chugai Pharmaceutical Co
7. Lifecore Biomedical
8. LG Life Sciences Ltd